

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **THE GROUP'S HYPERTENSION AND DYSLIPIDEMIA COMBINATION DRUG “LEVAMLODIPINE MALEATE/ATORVASTATIN CALCIUM TABLET” COMMENCES PHASE III CLINICAL TRIAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries (the “**Group**”)) announces that “Levamlodipine Maleate/Atorvastatin Calcium Tablet” (the “**Product**”) developed by the Group has officially commenced phase III clinical trial upon passing the assessment by the ethics committee of Beijing Anzhen Hospital of the Capital Medical University. Currently, 1 case has been enrolled into the study.

Levamlodipine Maleate/Atorvastatin Calcium Tablet is a combination preparation of levamlodipine maleate and atorvastatin calcium developed by the Group. It is an innovative drug classified under chemical drug Class 1.5 in China. It was granted the approval for clinical trial by the China Food and Drug Administration on 5 January 2012.

The Product can treat hypertension and dyslipidemia simultaneously. For patients with both hypertension and dyslipidemia, effective management of blood pressure and blood lipids can significantly lower the risk of cardiovascular diseases. Combination preparation can improve patient compliance by minimising the inconvenience of morning and night dosage of antihypertension drug and lipid-lowering drug. It can also promote simultaneous attainment of blood pressure and blood lipids targets, significantly lowering the risk of cardiovascular diseases. In addition, the combination preparation has higher efficacy than single drug treatment of amlodipine.

Hypertension is the most common chronic disease and is also the most major risk factor for cerebro-cardiovascular diseases. Its major complications include stroke, myocardial infarction, heart failure and chronic renal diseases. Dyslipidemia is an important risk factor for diseases associated with atherosclerosis. The coexistence of hypertension and dyslipidemia significantly increases the risk of cardiovascular diseases. Patients with both hypertension and dyslipidemia should receive active antihypertension treatment and appropriate lipid-lowering treatment at the same time.

The Group has been dedicated to developing the cardiovascular drugs market. The successful development of the antihypertension drug “Xuanning” (levamlodipine maleate) has formed a solid market foundation for the Group and built favourable market conditions for the launch of Levamlodipine Maleate/Atorvastatin Calcium Tablet in the future. The Product will be one of the key drugs under research and development in the cardiovascular area of the Group in the forthcoming years. The successful commencement of phase III clinical trial has also provided strong momentum for the drug research and development of the Group.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 19 December 2014

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo and Mr. WANG Jinxu as executive Directors; Mr. LEE Ka Sze, Carmelo as non-executive Director and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Shilin as independent non-executive Directors.*